Evaluation of blood levels of Paclynap produced drug in Iran in comparison with Abraxan in pancreatic cancer patients

Phase 1

• Conditions: Pancreas cancer.; Malignant neoplasm of pancreas

• Registration Number: IRCT2016041118745N4
• Lead Sponsor: ano Daru Pajuhan Pardis Co

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

inclusion criteria: with written consent; patients with Local Advanced Pancreatic Cancer.
exclusion criteria: patients with hepatic and renal disorders; patients with acute and chronic heart disease; patients with pulmonary and cerebral metastasis; patient with decreased albumin levels of two times of normal; patients with enhanced blood bilirubin of 3 times over.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Paclytaxel serum level. Timepoint: 30 min, one, two, four, six, eight, twelve, twenty four, forty eight hours after injection. Method of measurement: High fluid pressure chromatography.

Secondary Outcome Measures

Name	Time	Method
Decrease of tumor. Timepoint: Two months after injection. Method of measurement: Imaging using MRI.